NIH stops portion of major diabetes study

02/6/2008 | Wall Street Journal (free content), The · Yahoo!

The NIH has stopped a part of a 10,251-patient study seeking the best strategy to prevent heart attack, stroke or death from cardiovascular disease among Type 2 diabetes patients. The decision was made after the finding of more deaths among those who took an aggressive approach to cutting blood-sugar levels than among those who used a moderate strategy. Researchers have yet to identify the cause for the higher death rate, and said they found no evidence linking the increase to diabetes drugs metformin and glitazones, or to any other drug.

View Full Article in:

Wall Street Journal (free content), The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance Director
Abbott Laboratories
Santa Clara, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Fremont, CA